Medtech Trauma and Extremities constant-currency sales growth measures product revenue growth after removing foreign-currency translation effects.
Stryker reported 11.5% constant-currency growth in Trauma and Extremities for the second quarter of 2026. Revenue increased to $1.072B from $957M.
Growth was double digit in the U.S. and international markets
U.S. revenue increased 12.5%, while international revenue grew 8.5% on a constant-currency basis.
The total rate therefore reflects broad growth rather than one geography alone.
Category revenue is broader than trauma procedure volume
The business includes products across trauma and extremities, so revenue can move with volume, mix, pricing, and technology adoption.
Read it with Ortho Tech constant-currency sales growth and Orthopaedics operating margin.
Primary source: Stryker Q2 2026 Form 10-Q.
Part of the Medtech Product Family Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- SYKOpen operating-model research →10 of 10 reviewed concepts in Medtech Product Family EconomicsOrthopaedics product growth4 of 4 bridge concepts supportedContinue through this bridge:Hips Constant-Currency GrowthKnees Constant-Currency GrowthOrtho Tech Constant-Currency Growth
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare trauma and extremities growth
Compare category growth with U.S. and international demand, product mix, pricing, and technology adoption kept in context.
Explore more topics in the Financial Research Encyclopedia.